A kind of medical packaging glass and preparation method thereof

Through the composition ratio and cluster model represented by the double-cluster molecular structural unit, borosilicate glass with excellent acid resistance and hardness was designed, which solved the problem of poor chemical stability of existing medical glasses and achieved high-performance medicine Packaging glass preparation.

CN116354600BActive Publication Date: 2024-12-03HAINAN UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202111626338.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-28
Publication Date
2024-12-03
Estimated Expiration
2041-12-28

AI Technical Summary

Technical Problem

The current domestic medical glass has poor chemical stability, especially low borosilicate glass, which cannot meet the foreign use requirements for neutral borosilicate glass and lacks systematic glass composition design guidance.

Method used

The composition ratio {M2O3}9{Si2O4}7 represented by the double-cluster molecular structural unit is used to construct the minimum structural unit of the glass through the cluster model, and a borosilicate glass with excellent acid resistance and hardness is designed. The specific components are Sodium oxide 6 to 7%, calcium oxide 0.5 to 1.2%, barium oxide 2 to 3%, boron oxide 10 to 11%, aluminum oxide 5 to 6%, silicon oxide 73 to 76%, and specific melting and annealing processes preparation.

Benefits of technology

The prepared pharmaceutical packaging glass has excellent acid resistance and hardness, meets the foreign use requirements for neutral borosilicate glass, and improves the chemical stability and processing performance of pharmaceutical glass.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure BDA0003438774420000061
    Figure BDA0003438774420000061
  • Figure BDA0003438774420000062
    Figure BDA0003438774420000062
Patent Text Reader

Abstract

The present invention provides a pharmaceutical packaging glass, which uses a double cluster molecular structural unit shown in Formula I to represent the composition ratio: {M2O3}9{Si2O4}7Formula I; in Formula I, M represents cations with +1 valence, +2 valence, +3 valence and +4 valence in the glass; the molar ratio of the cations with +1 valence, +2 valence, +3 valence and +4 valence is 6:1:12:13. The present invention introduces a cluster model, and uses the model to construct a class of molecular structural units, which is the smallest structural unit of glass. According to the ratio of each element in the cluster expression of the class of molecular structural units, borosilicate glass suitable for pharmaceutical packaging is prepared, providing a new method and pointing out a new path for the composition design of glass. According to the molar ratio of the components in the expression of the present invention, the prepared glass has excellent acid resistance and hardness. The present invention also provides a method for preparing pharmaceutical packaging glass.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical packaging materials, and in particular relates to pharmaceutical packaging glass and a preparation method thereof. Background Art

[0002] Borosilicate glass has the characteristics of high visible light transmittance, low expansion coefficient, good chemical stability, excellent heat resistance and impact energy. It is widely used in aerospace, lighting, solar energy, fire protection, deep-sea exploration windows or instrument cabins, pharmaceutical packaging, high-temperature resistant instruments and other fields.

[0003] In the field of pharmaceutical glass packaging, low borosilicate glass and soda-lime glass are still the main materials in China. Although they are low in cost, they have poor chemical stability. According to the "In-depth Research and Investment Strategy Report on China's Pharmaceutical Glass Packaging (2019 Edition)", the use of neutral borosilicate in domestic pharmaceutical glass accounted for only 7-8% in 2018. The United States, Europe, Japan and Russia all require all injectable preparations and biological preparations to be packaged in neutral borosilicate glass. Neutral borosilicate glass has been widely used in the foreign pharmaceutical industry, and its mainstream products have an expansion coefficient of (3.3±0.1)×10 -6 / K (boron 33 for short) and expansion coefficient (5.0±0.1)×10 -6 / K (boron 50 for short) borosilicate glass. However, due to the low expansion coefficient of boron 33, the post-processing of the glass shape is limited, so boron 50 glass is more widely used. With the development of my country's pharmaceutical industry, the requirements for the use of neutral boron glass are gradually increasing, which has promoted the research and development and production of boron 50 glass.

[0004] Glass composition plays a decisive role in glass performance, but in terms of glass composition design, the boron 50 glass currently produced in my country basically follows foreign products and conducts experiments and explorations before being put into production, and there is a serious lack of systematic theoretical guidance. Summary of the invention

[0005] The object of the present invention is to provide a pharmaceutical packaging glass and a preparation method thereof. The present invention proposes a new design scheme for glass composition. The pharmaceutical packaging glass obtained according to the scheme has excellent acid resistance and hardness.

[0006] The present invention provides a pharmaceutical packaging glass, which adopts a double-cluster molecular structural unit shown in Formula I to represent the composition ratio:

[0007] {M2O3}9{Si2O4}7 Formula I;

[0008] In formula I, M represents +1-valent, +2-valent, +3-valent and +4-valent cations in the glass; the molar ratio of the +1-valent, +2-valent, +3-valent and +4-valent cations is 6:1:12:13.

[0009] Preferably, the average coordination number of the pharmaceutical packaging glass is 3.35 to 3.45.

[0010] Preferably, the +1 cation is Na + ; +2 cation is Ca 2+ , Ba 2+ and Mg 2+ One or more of the following; +3 cation is B 3+ and / or Al 3+ ; +4 cation is Si 4+ .

[0011] Preferably, Na in the M + , Ca 2+ , Ba 2+ , B 3+ 、Al 3+ and Si 4+ The molar ratio is (3~3.5):(0.2~0.3):(0.2~0.3):(5~5.5):(1.5~1.8):(7~8).

[0012] Preferably, the pharmaceutical packaging glass has the following components by mass fraction:

[0013] Sodium oxide: 6-7%; calcium oxide: 0.5-1.2%; barium oxide: 2-3%, boron oxide: 10-11%, aluminum oxide: 5-6%, silicon oxide: 73-76%.

[0014] Preferably, the pharmaceutical packaging glass has the following components:

[0015] Sodium oxide: 6.12976%; calcium oxide: 0.924367%; barium oxide: 2.527356%, boron oxide: 10.32776%, aluminum oxide: 5.04193%, silicon oxide: 75.0488%.

[0016] The present invention provides a method for preparing the pharmaceutical packaging glass as described above, comprising the following steps:

[0017] A) mixing the raw materials and placing them in a crucible at 1100-1300° C., heating them to 1300-1600° C., and then further heating them to 1600-1700° C., melting and clarifying them for 3-5 hours to obtain glass liquid;

[0018] B) casting the glass liquid to obtain a semi-finished product;

[0019] C) annealing the formed semi-finished product to obtain medical packaging glass.

[0020] Preferably, the heating rate in step A) is 1-5°C / min.

[0021] Preferably, the annealing temperature in step C) is 500-800° C. and the annealing time is 1-3 hours.

[0022] Preferably, the step A) is specifically:

[0023] The raw materials are mixed, and the obtained mixture is added into a crucible at 1100-1300°C. After the temperature is raised to 1300-1600°C, a second feed is added, and the temperature is further raised to 1600-1700°C, and then melted and clarified for 3-5 hours to obtain glass liquid.

[0024] The present invention provides a pharmaceutical packaging glass, which uses a double cluster molecular structural unit shown in Formula I to represent the composition ratio: {M2O3}9{Si2O4}7 Formula I; in Formula I, M represents +1-valent, +2-valent, +3-valent and +4-valent cations in the glass; the molar ratio of the +1-valent, +2-valent, +3-valent and +4-valent cations is 6:1:12:13. The present invention introduces a cluster model, and uses the model to construct a class of molecular structural units, which is the smallest structural unit of glass. According to the ratio of each element in the cluster expression of the class of molecular structural units, borosilicate glass suitable for pharmaceutical packaging is prepared, providing a new method and pointing out a new path for the composition design of glass. According to the molar ratio of the components in the expression of the present invention, the prepared glass has excellent acid resistance and hardness. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0026] Figure 1 It is a schematic diagram of the cluster structure of the traditional Chinese medicine packaging glass of the present invention. DETAILED DESCRIPTION

[0027] The present invention provides a pharmaceutical packaging glass, wherein the composition ratio is represented by a double-cluster molecular structural unit as shown in Formula I:

[0028] {M2O3}9{Si2O4}7 Formula I;

[0029] In formula I, M represents cations with a valence of +1, +2, +3, and +4 in the glass.

[0030] The present invention uses the cluster plus connected atomic model to analyze the composition of glass and proposes that {M2O3}9{Si2O4}7 is the idealized minimum structural unit (i.e., a quasi-molecular structural unit). The entire glass can be regarded as a stack of this minimum structural unit. For details, see Figure 1 , Figure 1 In which {M2O3} is a trivalent structural unit, the 32 M cations form Na6Mg1B 12 Si 13 . The {M2O3} and {Si2O4} structural units are stacked to form the following supercluster structure model. Each ball represents a structural unit of a cluster plus connecting atoms, arranged in the stacking mode of the molecular structural unit {Si2O4} in β-SiO2. The first nearest neighbor forms a twinned cuboctahedron. The central unit position is marked with a dotted arrow and is occupied by {Si2O4}. Among the 12 shell units, 6 horizontal units are occupied by {Si2O4}, and 3 upper and lower units are occupied by 6 {M2O3}. The connecting unit is located at the next nearest neighbor, forming a triangular prism with a coordination number of 6, marked with a red ball (only two positions are drawn for clarity), which is occupied by 3 {M2O3} here.

[0031] Glass with good performance can be prepared by adjusting the molar ratio of elements in the idealized minimum structural unit, or by replacing elements of the same group with the assistance of appropriate processes.

[0032] In the present invention, Formula I is a double cluster formula, in which there are 9 clusters {M2O3} and 7 {Si2O4}, the total number of cations is 32, and the average coordination number is between 3.35 and 3.45; the average coordination number of cations in {M2O3} is 3.

[0033] In the present invention, M in Formula I includes cations with a valence of +1 to +5 in the glass, and can be regarded as an average representation of cations with a valence of +1 to +5 in the glass.

[0034] According to the molecular structural unit formula 32 cationic formula {M2O3}9{Si2O4}7 and its coordination number characteristics, and considering the feasibility of the preparation process, the present invention relates to a glass with the following composition:

[0035] The +1 cation is Na + ; +2 cation is Ca 2+ , Ba 2+ and Mg 2+ One or more of the following; +3 cation is B 3+ and / or Al 3+ ; +4 cation is Si 4+ .

[0036] Preferably, Na in the M+ , Ca 2+ , Ba 2+ , B 3+ 、Al 3+ and Si 4+ The molar ratio is (3-3.5):(0.2-0.3):(0.2-0.3):(5-5.5):(1.5-1.8):(7-8), and more preferably 3.375:0.28125:0.28125:5.0625:1.6875:7.3125.

[0037] Based on this, the Na in pharmaceutical packaging glass is represented by the double cluster molecular structure unit shown in Formula I. + , Ca 2+ , Ba 2+ , B 3+ 、Al 3+ and Si 4+ The molar ratio is 3.375:0.28125:0.28125:5.0625:1.6875:(7.3125+14), that is 3.375:0.28125:0.28125:5.0625:1.6875:21.3125.

[0038] Converted into mass percentage, the Chinese medicine packaging glass of the present invention has the following components by mass fraction:

[0039] Sodium oxide: 6-7%; calcium oxide: 0.5-1.2%; barium oxide: 2-3%, boron oxide: 10-11%, aluminum oxide: 5-6%, silicon oxide: 73-76%.

[0040] More preferably, the components have the following mass fractions:

[0041] Sodium oxide: 6.12976%; calcium oxide: 0.924367%; barium oxide: 2.527356%, boron oxide: 10.32776%, aluminum oxide: 5.04193%, silicon oxide: 75.0488%.

[0042] The present invention also provides a method for preparing pharmaceutical packaging glass, comprising the following steps:

[0043] A) mixing the raw materials and placing them in a crucible at 1100-1300° C., heating them to 1300-1600° C. and then feeding them again, and further heating them to 1600-1700° C. and then melting and clarifying them for 3-5 hours to obtain glass liquid;

[0044] B) casting the glass liquid to obtain a semi-finished product;

[0045] C) annealing the formed semi-finished product to obtain medical packaging glass.

[0046] The present invention first preheats the crucible, then places the uniformly mixed raw materials in the crucible and heats the crucible to 1300-1600° C.

[0047] In the present invention, the preheating temperature is preferably 1100-1300° C., more preferably 1200-1250° C.; the raw materials may be of the types and proportions described above, which will not be elaborated herein.

[0048] In the present invention, the heating rate is preferably 1-5°C / min, more preferably 2-4°C / min, and most preferably 3°C / min.

[0049] In the present invention, the temperature is raised to 1300-1600° C., more preferably 1400-1500° C., and then the secondary material is fed, and then the temperature is raised to 1600-1700° C. to melt and clarify to obtain molten glass.

[0050] In the present invention, the heating rate is preferably 1-5°C / min, more preferably 2-4°C / min, and most preferably 3°C / min.

[0051] In the present invention, the secondary feed has the same ingredients as the first feed. The present invention preferably adds the secondary feed after the raw material is heated to 1300-1600°C and melted. On the one hand, since the carbonate raw material has a low decomposition temperature, the first batch of feed can decompose it first, expel the gas, and make clarification easier. On the other hand, it can avoid overflow.

[0052] The temperature of the melting and clarification is preferably 1600-1700° C., more preferably 1650° C.; the time of the melting and clarification is preferably 3-5 hours, more preferably 4 hours.

[0053] After obtaining the glass liquid, the present invention pours the glass liquid onto a steel plate for casting, anneals the formed glass in a muffle furnace to eliminate the internal stress of the glass, and then cools the glass to room temperature with the furnace to obtain colorless and transparent medical packaging glass.

[0054] In the present invention, the annealing temperature is preferably 500-800° C., more preferably 600-700° C.; the annealing time is preferably 1-3 hours, more preferably 2 hours.

[0055] The present invention provides a pharmaceutical packaging glass, which uses a double cluster molecular structural unit shown in Formula I to represent the composition ratio: {M2O3}9{Si2O4}7 Formula I; in Formula I, M represents +1-valent, +2-valent, +3-valent and +4-valent cations in the glass; the molar ratio of the +1-valent, +2-valent, +3-valent and +4-valent cations is 6:1:12:13. The present invention introduces a cluster model, and uses the model to construct a class of molecular structural units, which is the smallest structural unit of glass. According to the ratio of each element in the cluster expression of the class of molecular structural units, borosilicate glass suitable for pharmaceutical packaging is prepared, providing a new method and pointing out a new path for the composition design of glass. According to the molar ratio of the components in the expression of the present invention, the prepared glass has excellent acid resistance and hardness.

[0056] In order to further illustrate the present invention, a pharmaceutical packaging glass and a preparation method thereof provided by the present invention are described in detail below in conjunction with embodiments, but it should not be construed as limiting the protection scope of the present invention.

[0057] Examples 1 to 6

[0058] Preheat the corundum crucible to 1200°C in a high-temperature furnace. Pour the uniformly mixed raw materials into the corundum crucible according to the ratio in Table 1. Heat the temperature to 1500°C at a heating rate of 3°C / min, then feed the secondary material. Heat the temperature to 1650°C at a heating rate of 3°C / min for melting and clarification for 3 hours. Pour the glass liquid on a steel plate for casting and forming. Put the formed glass into a muffle furnace at 600°C for 2 hours for annealing to eliminate the internal stress of the glass. Then cool it to room temperature with the furnace to obtain a colorless and transparent glass product.

[0059] Table 1 Ingredient ratios in Examples 1 to 6

[0060]

[0061] Note: Due to the inevitable errors in the calculation process, the sum of the mass fractions of silicon oxide, boron oxide, aluminum oxide, sodium oxide, calcium oxide and barium oxide in Table 1 is not strictly equal to 100wt%.

[0062] The glass products in Examples 1 to 6 were tested for performance according to the following method:

[0063] The prepared glass samples were cut into strips with a size of 4 mm × 4 mm × 40 mm and tested separately. The heating rate was 5 °C / min, the temperature range was 20 °C to 380 °C, and records were made.

[0064] The sample was cut into small pieces of 8 mm × 30 mm × 30 mm, and corroded in a 10% HF solution at 25±5°C for 20 min. The mass before and after corrosion was weighed and the mass difference was calculated.

[0065] Cut the sample into small pieces of 8mm×30mm×30mm, and corrode them in a 5% NaOH solution at 85±5℃ for 6h. Weigh the mass before and after corrosion and calculate the mass difference. Observe whether there is no turbidity, discoloration, cracks, etc.

[0066] The samples were cut, ground and polished to a thickness of about 8 mm, cut into small pieces of about 30 mm × 30 mm, and tested 5 times. The force of the test indenter was 100 gf, the test results were recorded, and the average value of the micro-Vickers hardness of each sample was calculated.

[0067] Table 2 Performance data of glass products in Examples 1 to 6

[0068]

[0069]

[0070] Comparative Example 1

[0071] The material used for the high borosilicate glass tube was obtained by ball milling using 78wt% silicon dioxide, 13wt% boron oxide, 5wt% antimony oxide, 0.4wt% potassium titanium oxalate, 3wt% sodium chloride, and 1.1wt% cerium oxide as raw materials. The high borosilicate glass was obtained by melting, and its thermal expansion coefficient is 33.5×10 -7 / ℃.

[0072] Comparative Example 2

[0073] Using 69.36wt% silicon dioxide, 14.97wt% aluminum oxide, 1.47wt% boron oxide, 0.64wt% magnesium oxide, 6.53wt% calcium oxide, 4wt% zinc oxide, 1wt% strontium oxide, and 0.1wt% stannous oxide as raw materials, a low expansion, high chemical stability alkali-free glass is prepared. Its thermal expansion coefficient is 31.25×10 -7 / ℃. Its chemical stability test, using 10% HF acid corrosion for 20 minutes at 22℃, the result is 4.81mg / cm 2 .

[0074] Comparative Example 3

[0075] A highly chemically durable alkali-free boroaluminosilicate glass is prepared using 60wt% silicon dioxide, 24wt% aluminum oxide, 5wt% boron oxide, 4.2wt% magnesium oxide, 2.5wt% zinc oxide, 3wt% zirconium oxide, 0.1wt% cadmium oxide, and 1.2wt% tin oxide as raw materials. The thermal expansion coefficient of the glass is 30.8×10 -7 / ℃. The acid resistance was tested by using 10% HF acid corrosion at 25±5℃ for 20min, and the result was 4.37mg / cm2 .

[0076] Comparative Example 4

[0077] The boroaluminosilicate glass substrate is composed of 59.8wt% silicon dioxide, 16.1wt% aluminum oxide, 9.65wt% boron oxide, 1.25wt% magnesium oxide, 6.2wt% calcium oxide, 3.2wt% strontium oxide, 2.63wt% barium oxide, 0.39wt% zinc oxide, 0.18wt% tin oxide and 0.25wt% cerium oxide, and its thermal expansion coefficient is 37×10 -7 / ℃.

[0078] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A pharmaceutical packaging glass, using a double cluster molecular structure unit as shown in Formula I to represent the composition ratio: {M2O3}9{Si2O4}7 Formula I; In formula I, M represents +1-valent, +2-valent, +3-valent and +4-valent cations in the glass; the molar ratio of the +1-valent, +2-valent, +3-valent and +4-valent cations is 6:1:12:13; The +1 cation is Na + ; +2 cation is Ca 2+ , Ba 2+ and Mg 2+ One or more of the following; +3 cation is B 3 + , or B 3+ and Al 3+ ; +4 cation is Si 4+ .

2. The pharmaceutical packaging glass according to claim 1, characterized in that: The average coordination number of the pharmaceutical packaging glass is 3.35 to 3.

45.

3. The pharmaceutical packaging glass according to claim 1, characterized in that: The M Na + , Ca 2+ , Ba 2+ , B 3+ 、Al 3+ and Si 4+ The molar ratio is (3~3.5):(0.2~0.3):(0.2~0.3):(5~5.5):(1.5~1.8):(7~8).

4. The pharmaceutical packaging glass according to claim 3, characterized in that: The pharmaceutical packaging glass has the following components by mass fraction: Sodium oxide: 6-7%; calcium oxide: 0.5-1.2%; barium oxide: 2-3%, boron oxide: 10-11%, aluminum oxide: 5-6%, silicon oxide: 73-76%.

5. The pharmaceutical packaging glass according to claim 4, characterized in that: The pharmaceutical packaging glass has the following ingredients: Sodium oxide: 6.12976%; Calcium oxide: 0.924367%; Barium oxide: 2.527356%, Boron oxide: 10.32776%, Aluminum oxide: 5.04193%, Silicon oxide: 75.0488%.

6. The method for preparing the pharmaceutical packaging glass according to claim 1, comprising the following steps: A) mixing the raw materials and placing them in a crucible at 1100-1300° C., heating them to 1300-1600° C., and then further heating them to 1600-1700° C., melting and clarifying them for 3-5 hours to obtain glass liquid; B) casting the glass liquid to obtain a semi-finished product; C) annealing the formed semi-finished product to obtain medical packaging glass.

7. The preparation method according to claim 6, characterized in that: The heating rate in step A) is 1-5°C / min.

8. The preparation method according to claim 6, characterized in that: The annealing temperature in the step C) is 500-800° C. and the annealing time is 1-3 hours.

9. The preparation method according to claim 6, characterized in that: The step A) is specifically as follows: The raw materials are mixed, and the obtained mixture is added into a crucible at 1100-1300°C. After the temperature is raised to 1300-1600°C, a second feed is added, and the temperature is further raised to 1600-1700°C, and then melted and clarified for 3-5 hours to obtain glass liquid.

Citation Information

Patent Citations

  • Preparation method of SiO2 film and its application

    CN102795788A

  • Method for preparing high-transparency high borosilicate glass tube

    CN104140205A

  • Glass composition and borosilicate glass made from glass composition and suitable for chemical enhancement

    CN104445926A

  • Composite clarifying agent, composition for neutral borosilicate medicinal glass as well as glass prepared from composition, and applications

    CN112624607A

  • Method for predicting dielectric constant of glass based on M5P algorithm

    CN113326664A